Conference Day One - Wednesday, April 30, 2025
7:00 am Registration & Coffee
7:55 am Chair’s Opening Remarks
Upcoming Breakthroughs in GLP-1s: Combinations to Improve, Efficacy, Tolerability & Patient Experience
8:00 am Beyond Incretins: Exploring the Quality of Weight Loss with AZD6234, a Novel Selective Amylin Receptor Agonist, and GLP-1RA Combinations in DIO Rats
Synopsis
- AZD6234 is a long-acting, selective amylin receptor agonist that mediates dose-dependent decreases in food intake and body weight change in obese rats
- Switching to AZD6234 after GLP1RA prevents body weight rebound and increases weight loss when combined with GLP1RA in obese rats
- AZD6234 promotes fat mass loss while preserving lean mass without compromising tolerability in pre-clinical models
8:30 am Examining the Latest Advancements in GLP-1-Based Therapies: Combining GLP-1 & Amylin Analogues for Obesity & Diabetes Therapy
Synopsis
- Discussing the complementary physiological actions of GLP-1 and amylin in regulating glucose homeostasis, appetite, and satiety
- Highlighting how the combination of agonists can lead to enhanced glycemic control, weight loss, and improved cardiovascular outcomes compared to monotherapies.
- Explore potential challenges, such as the development of long-acting dual agonists with sustained efficacy and the need for further clinical trials to establish long-term safety and efficacy
9:00 am New Insulin Sensitizers as a Golden Combination With Glp-1 & Weight Loss Therapies
Synopsis
- Discussing novel oral insulin sensitizers targeting the mitochondrial pyruvate carrier to improve insulin sensitivity by shifting mitochondrial metabolism, increasing insulin response, and enhancing mitochondrial function
- Exploring insulin sensitizers beyond glycaemic control such as their potential to increase lean muscle mass and inflammation modulation
- Developing potent insulin-sensitising drugs that can be used in combination with GLP-1 receptor agonists to meet the large unmet need in the management of individuals with type 2 diabetes
9:30 am Preclinical Assessment of GLP-1 and Combination Therapies for Obesity: Insights from Mouse Models
Synopsis
- Assessment of Mono, Dual, and Tri-Agonist GLP-1 Therapies in Diet-Induced Obese and db/db Mouse Models
- Effects of GLP-1 Agonists on Weight Reduction and Body Composition in a Polygenic Mouse Model Under Ambient and Thermoneutral Conditions
- Imaging Approaches for Body Composition Assessment in Preclinical Models: Subcutaneous Fat, Visceral Adiposity, and Lean Mass
10:00 am Speed Networking
Synopsis
Put a face to a name – this session is the perfect opportunity to get face-to-face time with key opinion leaders, leading companies, and innovative researchers in the GLP-1 field. Establish meaningful connections to build upon for the rest of the conference and gain individual insight beyond the papers and press releases into the pioneering research and technique applications.
10:30 am Morning Break & Networking
Increasing Muscle Preservation During GLP-1 Treatment for Improved Metabolic Function
11:00 am Combining GLP-1s with Anti-myostatin Monoclonal Antibodies for Improved Muscle Mass Retention
Synopsis
- Adding anti-myostatin to semaglutide treatments to improve quality of weight loss
- Exploring combination therapies to promote the maintenance of weight loss post GLP-1 administration
- Exploring the use of myostatins for the preservation of muscle mass during and after treatment using GLP-1s
11:30 am MRI-based Body Composition Reimagined: Building a New Foundation for Treatment Differentiation Beyond Weight Loss
Synopsis
- FDA-cleared MRI-based body composition analysis provides a new standard for muscle and fat quantification enabling translation from population studies and clinical trials all the way into healthcare
- Studies on Personalized Fat and Muscle Z-score biomarkers show improved prediction of outcomes and that weight- and BMI-invariant treatment effects can be detected
- Understanding loss of muscle mass and shifts in fat distribution in the context of weight reduction and exploring the varying effects of liraglutide and tirzepatide in recent clinical trials
12:00 pm Considerations for Aging Users of GLP-1s Using Sarcopenia as a Case Study
Synopsis
- Discussing the potential impact of GLP-1 receptor agonists on sarcopenia in aging populations
- Exploring the complex interplay between GLP-1 signaling, muscle mass, and function
- Examining the potential for GLP-1s to contribute to muscle loss or, conversely, to have beneficial effects on muscle mass and function in older adults
12:30 pm Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass and Physical Function in Older Patients Receiving Semaglutide for Weight Loss
1:00 pm Lunch & Networking
Novel Clinical Development & Design Strategies for the Assessment of GLP-1s in Obesity Related Conditions
2:00 pm Overcoming Complex Pathophysiology & Patient Retention in Clinical Trials for GLP-1s to Treat MASH
Synopsis
- Discussing the benefits of placebo sharing strategies to overcome challenges in placebo arm requirements in clinical trials
- Outlining strategies for placebo patient retention when other GLP-1 trials are available
- Evaluating the use of real-world placebo patient databases to execute reliable time to event analysis
2:30 pm Future of GLP1 Trials: Innovations and Perspectives
Synopsis
This comprehensive presentation will provide an in-depth overview of:
- Evolving trial designs
- Integrating technology in GLP1 Trials
- Future trends and implications
3:00 pm Panel: Delving into Clinical Trial Design to Accurately Assess GLP-1s in Comorbidities of Obesity
Synopsis
- Exploring strategies for patient selection and stratification using baseline characteristics and specific comorbidities to assess differential treatment effects
- Considering the ethical implications of placebo arms to obtain reliable clinical data whilst ensuring patients receive required care
- Drawing on real world data to ensure adequate sample size and statistical testing to detect clinically meaningful differences
3:30 pm How Imaging can Elucidate Effect of Incretin Therapies – from Muscle Preservation to Neuroprotection
Synopsis
- Insights from imaging: Advanced imaging methods to further understand the underlying mechanisms of incretin based pharmacological interventions
- Underneath the lost kilos: using body and muscle composition to understand the complexity of weight loss
- The future for incretin-based therapies: utilising imaging to elucidate novel combinations and expansion into new indications and disease areas
4:00 pm Afternoon Refreshments & Poster Session
Synopsis
Immerse yourself in an engaging and informal session, join your peers in a relaxed atmosphere that encourages meaningful conversations and discussions. Explore a range of exciting poster presentations and showcase your own developments in the GLP-1 Therapeutic world. Don’t miss out on the chance to submit your own posters and get ready to connect, learn, and present. To submit your poster please contact [email protected]
4:30 pm The Effects of GLP-1 Receptor Agonists on Lean Body Mass Loss & Associated Outcomes in Clinical Trials
Synopsis
- Navigating the rationale behind using GLP-1s to treat obesity, MASH and fatty liver disease
- Understanding the limitations of GLP-1 monotherapy and GLP-1/GIP dual agonists
- Strategies to increase the lean body mass retention of GLP-1 patients
5:00 pm DD01 – GLP-1/Glucagon Dual Agonist for the Treatment of MASH
Synopsis
- Developing a once weekly dual agonist of GLP-1 and glucagon receptors
- Exploring the benefits of half-life extension in obese/overweight patients with type 2 diabetes and MAFLD
- Assessing the benefits of DD01 in its ability to augment incretin therapy, acting through the glucagon receptor and enhancing liver lipolysis to treat the liver first
Forging Strategic Alliances Across Biotech, Pharma & Investors to Turbocharge Commercial & Scientific Breakthroughs in GLP-1 Development
5:30 pm Panel Discussion
Synopsis
- Hear from large pharma, investors, and experienced biotech leaders as they dive into the scientific and commercial factors of a setting up a successful partnership to develop GLP-1 based therapeutics for indications in obesity and beyond
- Uncover the key end-to-end key milestones that are evaluated when deciding on investment and partnership opportunities
- Ask your questions on what big pharma companies will be looking for next in their obesity and metabolism portfolios